KEYNOTE-564: Adjuvant Pembrolizumab vs Placebo After Nephrectomy for Renal Cell Carcinoma

June 4-8, 2021; Online at https://conferences.asco.org/am
Results of the first interim analysis for this randomized, double-blind phase III trial demonstrated significantly improved DFS with adjuvant pembrolizumab in patients with clear-cell RCC following nephrectomy.
Format: Microsoft PowerPoint (.ppt)
File Size: 501 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Commentary with expert answers to healthcare professional questions on adjuvant therapy for renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Commentary with expert answers to healthcare professional questions on therapy for metastatic renal cell carcinoma, from Clinical Care Options (CCO)

Brian A. Costello, MD, MS Eric Jonasch, MD Elizabeth R. Plimack, MD, MS Released: April 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings